Table 1

Clinical information on the analysed patients with UC

NoGenderAgeMayo Score (endoscopic 0–3)Histological assessmentMedicationRelapses/year (disease onset)*PSC**
 1M470A, L5-ASA<1x
 3M260A, L, E5-ASA+azathioprine<1
 6M530A5-ASA+TNFa inhibitors†<1
10M270A5-ASA(Onset 2011)
11F220L, C5-ASA+steroids(Onset 2011)
17M380NAD5-ASA(Onset 2011)
18F651A, L, E, P, N, C, CA5-ASA<1
19F371L, E, C, CA5-ASA<1
20M522L, E, P, CA, U5-ASA(Onset 2008)
21M282A, L, E, C, CA5-ASA(Onset 2009)
22F312A, L, E, C5-ASA≥1
23M363A, L, N, D5-ASA+azathioprine≥1
24M621A, L, C5-ASA+steroids≥1
25M262A, L, E, P, C, CA5-ASA+azathioprine≥1
26M452A, L, C5-ASA+azathioprine≥1
27M182A, L, E, P, C, CA, D, U5-ASA+azathioprine≥1
28F211A, L, E, P5-ASA+TNFα inhibitors≥1
  • *For patients with recent disease onset, the number of relapses cannot be given. Instead year of debut is stated in parentheses.

  • **PSC, primary sclerosing cholangitis. x, means present.

  • †Medication with TNFα inhibitor for rheumatoid arthritis.

  • ‡This patient had inflammation in more proximal part.

  • 5-ASA, 5-aminosalicylic acid; A, alterations in crypt architecture; C, cryptitis; CA, crypt abscesses; D, denuded epithelium; E, eosinophils; F, female; L, lymphocytes; M, male; N, neutrophils; NAD, nothing abnormal detected; P, plasma cells; PSC, primary sclerosing cholangitis; TNF, tumour necrosis factor; U, ulceration; UC, ulcerative colitis.